iSpecimen Inc. (NASDAQ:ISPC) Sees Significant Increase in Short Interest

iSpecimen Inc. (NASDAQ:ISPC) was the target of a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 241,056 shares, an increase of 113.6% from the May 14th total of 112,840 shares. Based on an average daily trading volume, of 386,118 shares, the short-interest ratio is presently 0.6 days. Approximately 19.1% of the shares of the company are short sold.

Wall Street Analyst Weigh In

ISPC has been the subject of a number of recent research reports. Wall Street Zen raised shares of iSpecimen to a “sell” rating in a research note on Saturday, May 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of iSpecimen in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, iSpecimen has a consensus rating of “Sell”.

Hedge Funds Weigh In On iSpecimen

A hedge fund recently bought a new stake in iSpecimen stock. Scientech Research LLC bought a new stake in iSpecimen Inc. (NASDAQ:ISPC) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned about 0.30% of iSpecimen as of its most recent filing with the Securities and Exchange Commission. 13.62% of the stock is currently owned by institutional investors.

iSpecimen Price Performance

Shares of iSpecimen stock remained flat at $2.75 during trading hours on Friday. The company’s stock had a trading volume of 108,522 shares, compared to its average volume of 234,752. The company has a market capitalization of $3.96 million, a P/E ratio of -0.04 and a beta of 1.62. iSpecimen has a 12 month low of $2.54 and a 12 month high of $127.20. The stock has a 50 day simple moving average of $4.39 and a 200 day simple moving average of $9.87.

iSpecimen (NASDAQ:ISPC) last announced its earnings results on Friday, May 15th. The company reported ($6.66) earnings per share for the quarter. The company had revenue of $0.16 million during the quarter. iSpecimen had a negative return on equity of 584.65% and a negative net margin of 1,080.16%.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.